Nagano Keiki (7715) · RiskMitigated
Excess Capacity and Impairment Risk Associated with Substantial Capital Investment
First written in FY2020. 1 of 2 entries say "Mitigated", first in FY2022. Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Investment Recovery and Impairment Risk for U.S. Manufacturing FacilitiesA theme 4 companies write about · 4 as a headwind · 0 as a tailwind
2 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022Explicit review of capital investment by the Product Review Committee and the Board of DirectorsAnnual report
「When considering the sale of new mass-produced products, the appropriateness of the related capital investment is reviewed in advance by the Product Review Committee. Significant investments are made only after approval by resolution of the Board of Directors, and we are taking steps to mitigate this risk.」
The response to the risk of excess capacity and impairment following substantial capital investment was specified as investment review through prior deliberation and Board of Directors approval. - FY2020First statedAnnual report
「However, if demand for the products falls significantly short of expectations relative to the substantial capital investment, the resulting burden of excessive depreciation expense, asset disposals and impairment could affect the performance of the Group.」
The risks of depreciation expense, asset disposals and impairment if demand declines following substantial capital investment were newly disclosed as a separate item.